AstraZeneca Respiratory Head: Tezepelumab Could Be 'Game Changer'
Executive Summary
AstraZeneca's first in class biologic tezepelumab, which targets TSLP, has revolutionary potential in treating severe asthma, the UK drug maker's respiratory head tells Scrip.